Related Experiment Video
Updated: May 25, 2026
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
[Bone metastasis in prostate cancer]
1Urologische Universitätsklinik, Inselspital Bern, Anna-Seiler-Haus, Freiburgstraße 10, CH-3010 Bern, Schweiz.
Abstract:
Bone metastasis and skeletal complications have a devastating impact on the quality of life and are a major cause of morbidity in prostate cancer patients. In addition to established bone-targeted therapies, new drugs such as endothelin A receptor antagonists, MET and VEGFR-2 antagonists or radiopharmaceuticals are in the focus of development. The standard care in prostate cancer patients with bone metastases to prevent skeletal-related events (SRE) are bisphosphonates. Denosumab, a human monoclonal antibody against RANKL, appeared to be superior to zoledronic acid for prevention of SRE and has been shown to prolong bone metastases-free survival. In contrast to zoledronic acid, denosumab clearance is not dependent on kidney function and can be administered subcutaneously. Similar rates of toxicity were observed for both substances; however, long-term data for denosumab are limited.
Insights
Denosumab, a RANKL inhibitor, is more effective than zoledronic acid in preventing skeletal events in prostate cancer bone metastases. It offers advantages in renal clearance and administration, though long-term safety data are still limited.
Area of Science:
- Oncology
- Pharmacology
Context:
- Prostate cancer frequently metastasizes to bone, causing significant morbidity and reduced quality of life.
- Skeletal-related events (SRE) are a major complication, necessitating effective preventative strategies.
Purpose:
- To compare the efficacy and safety of denosumab versus zoledronic acid in preventing SRE in prostate cancer patients with bone metastases.
- To review emerging therapies targeting bone metastasis in prostate cancer.
Summary:
- Denosumab, a monoclonal antibody targeting RANKL, demonstrated superiority over zoledronic acid in preventing SRE and prolonging bone metastasis-free survival.
- Unlike zoledronic acid, denosumab's clearance is independent of renal function and it is administered subcutaneously.
- Both treatments showed similar toxicity profiles, but long-term denosumab data are limited.
Impact:
- Denosumab offers a potentially more convenient and effective option for managing bone metastases in prostate cancer.
- This review highlights the evolving landscape of bone-targeted therapies and the importance of comparative effectiveness research.
